27 August 2014 Method measuring oxygen tension and transport within subcutaneous devices
Author Affiliations +
J. of Biomedical Optics, 19(8), 087006 (2014). doi:10.1117/1.JBO.19.8.087006
Abstract
Cellular therapies hold promise to replace the implantation of whole organs in the treatment of disease. For most cell types, <italic<in vivo</italic< viability depends on oxygen delivery to avoid the toxic effects of hypoxia. A promising approach is the <italic<in situ</italic< vascularization of implantable devices which can mediate hypoxia and improve both the lifetime and utility of implanted cells and tissues. Although mathematical models and bulk measurements of oxygenation in surrounding tissue have been used to estimate oxygenation within devices, such estimates are insufficient in determining if supplied oxygen is sufficient for the entire thickness of the implanted cells and tissues. We have developed a technique in which oxygen-sensitive microparticles (OSMs) are incorporated into the volume of subcutaneously implantable devices. Oxygen partial pressure within these devices can be measured directly <italic<in vivo</italic< by an optical probe placed on the skin surface. As validation, OSMs have been incorporated into alginate beads, commonly used as immunoisolation devices to encapsulate pancreatic islet cells. Alginate beads were implanted into the subcutaneous space of Sprague–Dawley rats. Oxygen transport through beads was characterized from dynamic OSM signals in response to changes in inhaled oxygen. Changes in oxygen dynamics over days demonstrate the utility of our technology.
Weidling, Sameni, Lakey, and Botvinick: Method measuring oxygen tension and transport within subcutaneous devices

1.

Introduction

Nonautologous tissue transplantation is a promising approach to overcome the scarcity of human pancreas donor tissue in the treatment of type 1 diabetes.12.3.4.5 To this end, we have developed a scalable islet of Langerhans (islet) isolation method wherein partially digested piglet pancreatic tissue is matured in vitro over 8 days by incubation in a novel cell culture media.6,7 During this period, exocrine tissue dies and isolated islets remain, which we have shown to be responsive to glucose challenges. Isolated islets can be encapsulated within permeable hydrogels such as alginate to provide an immunoprotective barrier that may preclude pharmacological immunosuppression.8,9 However, encapsulation devices introduce a transport barrier between the host and graft tissues and inherently limit oxygen supply, compromising graft function and cell viability,10 problems that scale with device wall thickness.11,12

Typically grafts are implanted in subcutaneous13 or intraperitoneal14 sites where partial pressures of oxygen (pO2) are approximately 60 and 40 mm Hg, respectively, which is lower than that of arterial blood (>80mmHg). It is commonly asserted that low cell viability within devices15,16 results from low tissue oxygen taken together with device diffusional barriers to create hypoxic and anoxic conditions, where these conditions are known to promote cell death through necrosis and apoptosis.17 However, direct measurement of oxygen levels within microencapsulated devices in vivo has not been previously reported, where such measurements are ultimately required to assay the efficacy of implant technologies that claim to promote oxygen delivery. In a study of relatively large alginate disc implants (1 to 1.5cm2 surface area at 3- to 6-mm thick) by Veriter et al.,18 oxygen within implanted devices was directly measured through the use of electronic paramagnetic resonance oximetry in rats. However, current research shows that such thick devices cannot retain islet function, likely due to diffusional limitations, thus promoting microencapsulation technologies such as thin sheets or microbeads of permeable materials.

We have developed a technology for the direct measurement of oxygen partial pressures within such implanted devices. Our technology comprises oxygen-sensitive microparticles (OSMs) and an electro-optical probe to noninvasively excite OSMs and record emitted light from which pO2 is determined. Additionally, we have developed a protocol to measure both the steady state pO2 within devices as well as transport dynamics between the device and the local vasculature. This is especially important for pancreatic islets transplantation because islets are metabolically demanding and are sensitive to decreases in tissue oxygenation. Although native islets contain an extensive capillary network,19 implanted devices typically do not, and are limited in their ability to supply oxygen to encapsulated pancreatic islets.10 Consequently, these islets are subject to hypoxic or anoxic conditions,15,16 contributing to the death of 40% of pancreatic islets in implants after just 4 weeks.20 Strategies aimed at improving oxygenation within biomaterial-encapsulated islets should significantly improve the chances of a successful transplant.21 These strategies can be tested with our technology to rule out approaches that do not mitigate a period of hypoxia post transplantation.

2.

Method for Preparing Alginate Beads Containing Oxygen Sensing Microparticles

2.1.

Preparation of OSMs

OSMs are made from an oxygen-sensitive dye embedded within a polystyrene matrix. Two types of OSMs were fabricated, each comprising a unique oxygen-sensing metalloporphyrin dye. The first is platinum(II) meso-tetraphenyl tetrabenzoporphine (PtTPTBP, Frontier Scientific, Logan) and the second is platinum(II) meso-tetra(pentafluorophenyl)porphine (PtTFPP, Frontier Scientific, Logan). OSMs are fabricated by first mixing 2 mg of dye with 30 mg of polystyrene (Mw 2500, Sigma, St. Louis) and then dissolving the mixture in 450μl of chloroform (Sigma). The solution is pipetted and spread onto a glass slide to polymerize overnight in room air at 23°C. The resulting thin film is scraped off with a razor blade and crushed into small micron-sized particles using a glass mortar and pestle.

2.2.

Encapsulation of OSMs Within Alginate Beads

Clinical grade ultrapure low viscosity alginate (UPLVM, Novamatrix, Sandvika, Norway) is dissolved in deionized water at 3 wt. % and sterile filtered using a 0.22μm syringe filter. OSMs are suspended in 1.5 mL of the UPLVM solution and loaded into an encapsulator (Nisco, Zurich, Switzerland) for the fabrication of alginate beads. Specifically, the solution is first loaded into a syringe and then driven through a 25 G needle under positive gas pressure (4 PSI, N2). The needle is held at 9 V relative to a 120 mM CaCl2 solution within a Petri dish placed below the tip of the needle. Alginate beads form at the tip of the needle and fall into the CaCl2 solution for alginate polymerization. A typical OSM alginate bead is shown in Fig. 1. Bead size is dependent on gas pressure, voltage, and the distance between the needle and media in the dish. For these experiments, the average diameter of alginate beads was found to be 415±47.68μm.

Fig. 1.

An alginate capsule containing oxygen-sensitive microparticle (OSM) sensors.

JBO_19_8_087006_f001.png

3.

Probing pO2 Within Alginate Beads

3.1.

Optical Probe for In Vitro Experiments

An optical probe was constructed to simultaneously measure both OSM types (Fig. 2). The two OSM types are spectrally separated. PtTFPP OSMs have multiple absorption peaks at 390, 504, and 538 nm and emission peaks at 647 and 710 nm.22 PtTPTBP OSMs have multiple absorption peaks at 430 and 614 nm and an emission peak at 770 nm.22 The optical probe can selectively excite either type of OSM with two pairs of light emitting diode (LEDs) (Rebel LED, Luxeon Star, Brantford, Canada) centered at 530 nm (green) and 617 nm (red) for PtTFPP and PtTPTBP, respectively. The LEDs are mounted onto a custom three-dimensional printed conical mount designed to pitch the LEDs such that emitted light converges onto samples placed just above the surface of the cone. The conical mount is glued onto the distal surface of a 2-in. long lens tube (Thorlabs, Newton) containing a 6.4-mm diameter image conduit (Edmund Optics, Barrington) and a focusing lens (f=25mm). The distal end of the lens tube is mounted onto a filter cube holder (Thorlabs) containing a long-pass dichroic beam splitter (FF740-Di01, Semrock, Rochester) to reflect PtTFPP and transmit PtTPTBP emissions, respectively. Two amplified photodiode detectors (PDA100A, 9.8-mm diameter, Gain=30, Thorlabs) are mounted onto the cube to detect emissions from each OSM type. LED emission and digitalization of photodiode signals are conducted by a National Instruments data acquisition device (USB6361 DAQ, National Instruments, Austin) controlled by LabView (National Instruments).

Fig. 2

Illustration of optical probe used for in vitro measurement. Emitted light from the two OSM types is separated spectrally onto two separate detectors.

JBO_19_8_087006_f002.png

3.2.

Determining Oxygen Partial Pressure From OSM Emission

OSMs were calibrated from measurements acquired at different pO2 levels, as provided by four gas tanks containing different oxygen mixtures. OSM emission was analyzed using the method of luminescence lifetime. OSMs were optically excited by pulsing LEDs in a 100 Hz square-wave with a 50% duty cycle. Optical signals were sampled at 1 MHz. OSMs were probed every 20 s, where at each time point, 25 measurements were acquired at 100 Hz and averaged. The metalloporphyrin dye within OSMs continues to emit light after the cessation of each LED light pulse. This emission is modeled as an exponential decay as

(1)

V(t)=V0e(tTau),
where V is the detector voltage, V0 is the voltage at the start of the decay, t is the time, and Tau is the lifetime decay time constant. Dye emission is quenched by oxygen and consequently, Tau decreases with increasing pO2. The relationship between pO2 and Tau is described by a modified Stern–Volmer relationship23

(2)

TauTau0=f1+KSV[O2]+1f,
where Tau is the oxygen-dependent lifetime decay time constant, Tau0 is the zero oxygen lifetime decay constant, f is the fraction of emission of one site of a two-site model,24 and KSV is the Stern Volmer constant. KSV and f were estimated by optimization.

3.3.

In Vitro Measurement of Oxygen Partial Pressure Within Alginate Beads

Alginate beads containing PtTPTBP OSMs and unencapsulated PtTFPP OSMs were suspended in 1 mL of media phosphate buffered saline (PBS) within a single well of a 24-well dish (Corning Inc., Corning) in which gas was bubbled (Fig. 3) with either compressed air (21% oxygen), or precalibrated mixtures of 10% oxygen/90% nitrogen, 5% oxygen/95% nitrogen, or argon gas (0% oxygen).

Fig. 3

(a) In vitro test system. Two spectrally distinct OSM types are suspended in a PBS bath within a well: one to monitor the PBS (green circles) and one to monitor the alginate capsules (red circles). (b) Close up view showing PBS and encapsulated OSMs within a well.

JBO_19_8_087006_f003.png

Figure 4 plots pO2 as reported by both the encapsulated and nonencapsulated OSMs versus time for a series of gas exchanges. The pO2 levels were calculated by first computing the mean steady state lifetime values for each gas concentration using Eq. (1). Regression of lifetime against gas concentration as computed by Eq. (2) (R2>0.99) provides a calibration equation mapping lifetime to pO2. Data confirms oxygen sensitivity within the alginate bead and no significant dynamic delay between the PBS and the volume of the bead (Fig. 4).

Fig. 4

In vitro measurements. pO2 for a set of gases containing oxygen at 21%, 10%, 5%, and 0%. Black line: pO2 in PBS and red line: pO2 in alginate capsules.

JBO_19_8_087006_f004.png

4.

Measuring pO2 and Transport Dynamics In Vivo

4.1.

In Vivo Probe

A compact in vivo optical probe was constructed for PtTPTBP OSMs alone [Fig. 5(a)]. Since only one dye is being measured in vivo there is no need for the more complex optical setup used in the in vitro experiment. Two of the 617-nm centered LEDs were mounted on the conical mount, as described above. The conical mount was then placed directly on the photodiode module and aligned with the active area of the photodiode. A 715 nm high-pass optical filter (Semrock) is mounted above the surface of the photodiode. The conical mount is placed directly onto the skin during measurements.

Fig. 5

In vivo measurements. (a) Optical probe used for in vivo measurements. (b) Day 5 pO2 and SpO2. Animals were anesthetized during measurements with a mixture of isoflurane and 100% oxygen.

JBO_19_8_087006_f005.png

4.2.

In Vivo pO2

In vivo testing was performed to determine if PtTPTBP OSM signals can be related to pO2 within subcutaneously implanted alginate beads. A small incision was made on the anterior side of an anesthetized rat (Sprague–Dawley, Charles River Laboratories, Wilmington). Anesthesia was maintained with a gas mixture of 100% oxygen and vaporized isoflurane delivered to a nose cone placed over the snout. OSM-containing beads were then implanted subcutaneously via pipette injection in a small pocket formed in the subcutaneous space by blunt dissection. The incision was closed using a wound sealing adhesive (Gluture, Abbott, Abbott Park). pO2 within beads was then optically probed on demand through the skin. Rats were fixed with a rodent pulse oximeter (Kent Scientific, Torrington) placed on the front paw to simultaneously measure oxygen saturation of blood hemoglobin (SpO2) and heart rate.

Figure 5(b) shows pO2 data acquired on day 5 post implantation during anesthesia. As expected, SpO2 was constant at normal physiological levels (95% to 100%) and pO2 within the beads was 100mmHg, indicating gas exchange both through the vasculature and skin.

The data collected in vivo was analyzed for its accuracy. Decay curves were collected as described above (measurements taken every 10 s with 25 curves for each measurement). After averaging the 25 curves, the variance at each point was found to be <0.5% of the mean value [Eq. (1)]. In the absence of OSMs, the detector returns an exponential decay of Tau 15μs. To determine the weight of this effect on OSM-mediated signals, the mean signal value between 0 and 50μs of OSM-mediated signals was divided by that for the OSM-free signals. The ratio was >7, which we found was insignificant for fitting OSM lifetimes.

4.3.

Variable Inhaled Gas Experiment

We developed an assay to measure transport dynamics between the microbeads and local vasculature. Such an assay is important since it captures effects of both increase/decrease of local vasculature resulting from the implantation wound and subsequent healing as well as the deposition of new collagenous tissue, which forms an additional diffusional barrier. Inhaled gas is rapidly changed as pO2 and SpO2 are monitored. Oxygen dynamics after each gas change are governed by tissue architecture, with rise/fall times increasing or decreasing as the local tissue rejects or perfuses the implant, respectively.

For these tests, the 100% oxygen + isoflurane inhaled gas was transiently exchanged with room air (21% oxygen) + isoflurane and then returned to 100% oxygen + isoflurane. OSMs were probed every 10 s. Measurements were recorded on days 5 and 9 post implantation.

Figure 6(a) shows a typical variable inhaled gas experiment at day 5. pO2 and SpO2 exhibited dynamics in the early stages of anesthesia (first 30 min) and eventually reached a steady state when breathing the 100% gas mixture. This phenomenon was common to most of our experiments and is likely due to the physiological effects of isoflurane. The gas was changed to the room air mixture for 10min and then returned to the 100% O2 mixture for 25min. pO2 within beads did not reach a steady state within the 10 min of room air, but did within the 25 min of 100% O2. Similar results were observed for the second room air challenge beginning at 72min.

Fig. 6

(a) Variable inhaled gas experiment. On day 5, SpO2 and pO2 within capsules consistently exhibit dynamics after the initiation of anesthesia, stabilizing after approximately 30 min. At 37 min, the percent oxygen mixed with isoflurane was changed from 100% to 21% for 11 min and then switched back. The same exchange in inhaled gas is repeated 26 min later. (b) On day 9, pO2 within capsules exhibits faster dynamics following a gas exchange as compared to day 5.

JBO_19_8_087006_f006.png

The variable inhaled gas experiment was repeated for the same rat on day 9 [Fig. 6(b)]. Here, pO2 reaches a steady state within the 10min of room air gas indicating rapid O2 exchange between the beads and tissues as compared to day 5, an effect most likely mediated by tissue remodeling.

5.

Conclusions and Future Directions

One of the great challenges for creating a successful nonautologous cellular therapy is to provide the new cells in the body with sufficient oxygen and nutrient transfer to survive while protecting them from the immune system. An array of techniques for encapsulating islet cells in alginate has been studied and tested extensively, but ultimately fail within weeks due to, in part, hypoxic conditions. We have developed a technique for measuring the oxygen concentration continuously inside an implanted object, such as an alginate bead, and verified its operation in vivo in rats by measuring its response to changing inhaled oxygen concentrations and comparing that response at two time points within the first week of implantation, during which wound healing is most active. The results showed that our technique tracks changes in oxygen in implanted alginate beads and that the rate of oxygen transfer to the implanted beads increased during the wound healing process. This link between wound healing and oxygen transport dynamics within the implanted microbeads could have implications for identifying designs that lead to either cell survival or cell death. By knowing the amount of oxygen inside the implants, one may be able to correlate that level with critical points in the wound healing process, such as new vessel formation or the identification of areas that have become “walled-off” from the body.

Optical oxygen sensing using luminescent dyes has gained popularity and is used in some commercial fiber-based optical oxygen probes, such as the Ocean Optics NeoFox system, and the PreSens oxygen probes (which can be used in biological applications). These devices show that the luminescence-based sensing of oxygen is reliable, but they fall short of being able to measure within implanted materials on small scales and would require a tethered component crossing the skin surface. Other technologies exist to noninvasively measure oxygen levels proximal to an implant, but these technologies do not measure oxygen within the device and thus cannot report on the microenvironment of encapsulated tissues. Such technologies include oxygen electrodes either implanted or in contact with skin,25,26 or scattered light methods such as diffuse optical spectroscopy (SpO2 measurement). Our technology has been demonstrated to continuously measure pO2 within implanted alginate microbeads using inexpensive optical components coupled to a standard data acquisition device. Microbead pO2 values measured subcutaneously in our study (45 to 120 mm Hg) were higher than those reported by Veriter et al. (5 to 40 mm Hg) where larger alginate devices were implanted in a similar manner. This difference can be attributed to differential tissue responses or the accuracy of the sensor. Our calibration against known gases had a regression coefficient of R2>0.99 indicating the accuracy of our system, and we have found that alginate microbeads elicit a moderate tissue response as compared to a slab (unpublished data). Future studies are planned to encapsulate islets along with OSMs and correlate pO2 with implant functionality and cell survival. This will provide quantitative evidence concerning the role of oxygen transport in reported failed approaches to islet encapsulation for reversal of type 1 diabetes. Additionally, our technique can evaluate new encapsulation technologies for their oxygen transport characteristics.

Acknowledgments

The authors would like to acknowledge Michael Alexander for providing training on animal procedures and providing technical support during animal procedures. E. Botvinick acknowledges the Air Force Office of Scientific Research (FA9550-10-1-0538) and the National Institutes of Health (P41EB015890). J. Lakey acknowledges financial and institutional support from Department of Surgery, University of California Irvine.

References

1. 

C. D. Chinget al., “A reliable method for isolation of viable porcine islets,” Arch. Surg. 136(3), 276–279 (2001).ARSUAX0004-0010http://dx.doi.org/10.1001/archsurg.136.3.276Google Scholar

2. 

C. G. ThanosR. B. Elliot, “Encapsulated porcine islet transplantation: an evolving therapy for the treatment of type I diabetes,” Expert Opin. Biol. Ther. 9(1), 29–44 (2009).EOBTA21471-2598http://dx.doi.org/10.1517/14712590802630666Google Scholar

3. 

D. Sutherlandet al., “Isolation of human and porcine islets of Langerhans and islet transplantation in pigs,” J. Surg. Res. 16(2), 102–111 (1974).JSGRA20022-4804http://dx.doi.org/10.1016/0022-4804(74)90017-1Google Scholar

4. 

M. LarsenB. Rolin, “Use of the Gottingen Minipig as a model of diabetes, with special focus on type 1 diabetes research,” ILAR J. 45(3), 903–313 (2004).http://dx.doi.org/10.1093/ilar.45.3.303Google Scholar

5. 

G. S. Korbuttet al., “Neonatal porcine islets as a possible source of tissue for humans and microencapsulation improves the metabolic response of islet graft post transplantation,” Ann. N. Y. Acad. Sci. 831(1), 294–903 (1997).ANYAA90077-8923http://dx.doi.org/10.1111/nyas.1997.831.issue-1Google Scholar

6. 

M. Lambet al., “In vitro maturation of viable islets from partially digested young pig pancreas,” Cell Transplant. 23(3), 263–272 (2013).CTRAE80963-6897http://dx.doi.org/10.3727/096368912X662372Google Scholar

7. 

C. Kuehnet al., “Young porcine endocrine pancreatic islets cultured in fibrin show improved resistance toward hydrogen peroxide,” Islets 5(5), 0–7 (2013).1938-2014http://dx.doi.org/10.1056/NEJM200007273430401Google Scholar

8. 

M. D. Darrabieet al., “Characteristics of poly-l-ornithine-coated alginate microcapsules,” Biomaterials 26(34), 6846–6852 (2005).BIMADU0142-9612http://dx.doi.org/10.1016/j.biomaterials.2005.05.009Google Scholar

9. 

P. de Voset al., “Multi scale requirements for bioencapsulation in medicine and biotechnology,” Biomaterials 30(13), 2559–2570 (2009).BIMADU0142-9612http://dx.doi.org/10.1016/j.biomaterials.2009.01.014Google Scholar

10. 

J. Schrezenmeiret al., “Long-term function of porcine islets and single cells embedded in barium-alginate matrix,” Horm. Metab. Res. 25(4), 204–209 (1993).HMMRA20018-5043http://dx.doi.org/10.1055/s-2007-1002077Google Scholar

11. 

K. ChowdaryK. P. MohapatraM. Krishna, “Evaluation of olibanum resin as a new microencapsulating agent for aceclofenac controlled release microcapsules,” Indian J. Pharm. Sci. 68(4), 461–464 (2006).http://dx.doi.org/10.4103/0250-474X.27818Google Scholar

12. 

K. Fehselet al., “Necrosis is the predominant type of islet cell death during development of insulin-dependent diabetes mellitus in BB rats,” Lab. Invest. 83(4), 549–559 (2003).http://dx.doi.org/10.1097/01.LAB.0000063927.68605.FFGoogle Scholar

13. 

N. Changet al., “Direct measurement of wound and tissue oxygen tension in postoperative patients,” Ann. Surg. 197(4), 470–478 (1983).ANSUA50003-4932http://dx.doi.org/10.1097/00000658-198304000-00017Google Scholar

14. 

R. B. Spokaneet al., “An implanted peritoneal oxygen tonometer that can be calibrated in situ,” ASAIO Trans. 36(3), M719–M722 (1990).ASATEJ0889-7190Google Scholar

15. 

J. Schrenzenmeiret al., “Effect of microencapsulation on oxygen distribution in islet organs,” Transplantation 57(9), 1308–1314 (1994).TRPLAU0041-1337Google Scholar

16. 

J. Schrezenmeiret al., “The role of oxygen supply in islet transplantation,” Transplant. Proc. 24(6), 2925–2929 (1992).TRPPA80041-1345Google Scholar

17. 

C. Michiels, “Physiological and pathological responses to hypoxia,” Am. J. Pathol. 64(6), 1875–1882 (2004).http://dx.doi.org/10.1016/S0002-9440(10)63747-9Google Scholar

18. 

S. Veriteret al., “In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation,” Tissue Eng. Part A 16(5), 1503–1513 (2010).1937-3341http://dx.doi.org/10.1089/ten.tea.2009.0286Google Scholar

19. 

S. Bonner-Weir, “Morphological evidence for pancreatic polarity of β-cell within islets of Langerhans,” Diabetes 37(5), 616–621 (1988).DIAEAZ0012-1797http://dx.doi.org/10.2337/diab.37.5.616Google Scholar

20. 

P. De Voset al, “Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?,” Diabetes 48(7), 1381–1388 (1999).DIAEAZ0012-1797http://dx.doi.org/10.2337/diabetes.48.7.1381Google Scholar

21. 

J. Schrezenmeiret al., “Immobilized hemoglobin improves islet function and viability in the bioartificial pancreas in vitro and in vivo,” Transplant. Proc. 26(2), 792–800 (1994).TRPPA80041-1345Google Scholar

22. 

M. QuarantaS. M. BorisovI. Klimant, “Indicators for optical oxygen sensors,” Bioanal. Rev. 4(2–4), 115–157 (2012).http://dx.doi.org/10.1007/s12566-012-0032-yGoogle Scholar

23. 

S. M. Borisovet al., “Phosphorescent platinum (II) and palladium (II) complexes with azatetrabenzoporphyrins—new red laser diode-compatible indicators for optical oxygen sensing,” ACS Appl. Mater. Interfaces 2(2), 366–374 (2010).AAMICK1944-8244http://dx.doi.org/10.1021/am900932zGoogle Scholar

24. 

E. R. Carrawayet al., “Photophysics and photochemistry of oxygen sensors based on luminescent transition-metal complexes,” Anal. Chem. 63, 337–342 (1991).ANCHAM0003-2700http://dx.doi.org/10.1021/ac00004a007Google Scholar

25. 

R. Ladurneret al., “Predictive value of routine transcutaneous tissue oxygen tension (tcpO2) measurement for the risk of non-healing and amputation in diabetic foot ulcer patients with non-palpable pedal pulses,” Med. Sci. Monit. 16(6), 273–277 (2010).MSMOFR1234-1010Google Scholar

26. 

D. De Backeret al., “Monitoring the microcirculation in the critically ill patient: current methods and future approaches,” Appl. Physiol. Intensive Care Med. 2, 263–275 (2012).http://dx.doi.org/10.1007/s00134-010-2005-3Google Scholar

Biography

John Weidling is a PhD student in the Department of Biomedical Engineering at the University of California, Irvine, United States. He is training in the laboratory of Elliot Botvinick. His dissertation work is the invention and development of a continuous lactate monitor for human health.

Sara Sameni is a PhD student in the Department of Biomedical Engineering at the University of California, Irvine, United States. She is training in the laboratories of Elliot Botvinick and Jonathan Lakey. Her dissertation work is the investigation of new technologies for xenotransplantation of pancreatic tissue in the treatment of type 1 diabetes.

Jonathan R. T. Lakey received his PhD degree in experimental surgery from the University of Alberta, Edmonton, Canada. He is an associate professor of surgery and biomedical engineering at the University of California, Irvine, United States. He is a director of the Clinical Islet Program and director of research in the Department of Surgery. He has research laboratories in the Department of Surgery and the Sue and Bill Gross Stem Cell Institute. He works in the areas of diabetes, islet transplantation, and stem cell biology.

Elliot Botvinick received his PhD degree in bioengineering from University of California, San Diego, United States. He is an associate professor of biomedical engineering and surgery at the University of California, Irvine, United States. He has research laboratories in the Beckman Laser Institute and the Edwards Lifesciences Center for Advanced Cardiovascular Technology. He works in the areas of mechano-biology, mechano-transduction, and tissue engineering.

John Weidling, Sara Sameni, Jonathan R. Lakey, Elliot L. Botvinick, "Method measuring oxygen tension and transport within subcutaneous devices," Journal of Biomedical Optics 19(8), 087006 (27 August 2014). http://dx.doi.org/10.1117/1.JBO.19.8.087006
Submission: Received ; Accepted
JOURNAL ARTICLE
5 PAGES


SHARE
KEYWORDS
Oxygen

Tissues

In vivo imaging

Light emitting diodes

Mercury

In vitro testing

Measurement devices

Back to Top